AEON Biopharma, Inc. (AEON)
AEON Biopharma is a clinical stage biopharmaceutical company focused on developing our proprietary botulinum toxin complex, ABP-450, for debilitating medical conditions.
ABP-450 is the same botulinum toxin complex that is currently approved and marketed for cosmetic indications by Evolus, Inc under the name Jeuveau. Botulinum toxins have proven to be a highly versatile therapeutic biologic, with over 230 therapeutic uses documented in published scientific literature and 10 approved therapeutic indications in the United States.
Our initial development programs for ABP-450 are directed at migraine, cervical dystonia and gastroparesis. Our Investigational New Drug application for ABP-450 as a preventative treatment for migraine was accepted by the FDA in the fourth quarter of 2020 and we initiated enrolling patients for our Phase 2 clinical study in the first quarter of 2021.
We plan to announce topline data related to our migraine study in the second half of 2022. Our IND application for ABP-450 as a treatment for cervical dystonia was accepted by the FDA in the third quarter of 2020 and we initiated our Phase 2 clinical study in the first quarter of 2021.
We plan to announce topline data in early 2022. In December 2020, we initiated a preclinical gastroparesis study. We expect to complete this preclinical study in the third quarter of 2021.
4040 MacArthur Blvd., Suite 260
Newport Beach, CA 92660
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Marc Forth||Chief Executive Officer and Director Nominee|
|Chris Carr||Chief Financial Officer|
|Chad Oh, M.D.||Chief Medical Officer|
|Simone Blank||Director, Chair|
|Jost Fischer||Director, Chairman Elect|
|Robert E. Grant||Director|
Latest SEC Filings
|Dec 29, 2021||RW||Registration Withdrawal Request|
|Oct 7, 2021||S-1/A||General form for registration of securities under the Securities Act of 1933|
|Oct 6, 2021||S-1/A||General form for registration of securities under the Securities Act of 1933|
|Oct 4, 2021||S-1/A||General form for registration of securities under the Securities Act of 1933|
|Sep 17, 2021||S-1||General form for registration of securities under the Securities Act of 1933|
|Sep 13, 2021||DRS/A||Draft Registration Statement|
|Jul 20, 2021||DRS/A||Draft Registration Statement|
|Jun 7, 2021||DRS/A||Draft Registration Statement|
|May 13, 2021||D/A||Notice of Exempt Offering of Securities|
|Aug 31, 2020||D||Notice of Exempt Offering of Securities|